Current treatment options in triple negative breast cancer

Area of Science:

• Oncology
• Genetics

Background:

• Triple negative breast cancer (TNBC) lacks specific molecular targets, making chemotherapy the standard treatment.
• TNBC often overlaps with basal-like and BRCA1-associated tumors, presenting a complex clinical challenge.
• Despite superior chemotherapy sensitivity, TNBC exhibits worse patient outcomes compared to other breast cancer subtypes.

Purpose of the Study:

• To review current evidence on chemotherapy and targeted therapies for TNBC.
• To analyze treatment effects and outcomes in neoadjuvant, adjuvant, and metastatic settings for TNBC.
• To inform treatment decisions for high-risk TNBC patients based on clinical trial data.

Main Methods:

• Review of select neoadjuvant, adjuvant, and metastatic chemotherapy clinical trials.
• Analysis of subgroup data focusing on TNBC and basal-like breast cancer outcomes.
• Synthesis of retrospective and prospective subgroup analyses and Phase II data.

Main Results:

• TNBC demonstrates significant, often superior, sensitivity to chemotherapy compared to other breast cancer subtypes.
• Existing evidence primarily stems from subgroup analyses and Phase II trials.
• Investigational therapies include platinum drugs, angiogenesis inhibitors, PARP inhibitors, and novel microtubule inhibitors.

Conclusions:

• Improved treatment strategies are needed for TNBC due to its aggressive nature and poor prognosis.
• Targeted therapies and DNA damaging agents are under investigation to enhance TNBC treatment efficacy.
• Evidence-based treatment decisions for TNBC should integrate data from various clinical trial settings.